
Pre-made Imalumab benchmark antibody ( Whole mAb, anti-MIF therapeutic antibody, Anti-GIF/GLIF/MMIF Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-265
Pre-Made Imalumab biosimilar, Whole mAb, Anti-MIF Antibody: Anti-GIF/GLIF/MMIF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Imalumab (BAX69) is an experimental monoclonal antibody against macrophage inhibitory factor (MIF), a cytokine known to exacerbate tumor growth. and as of January 2017 it is being tested in Phase IIa clinical trials for metastatic colorectal cancer. It was developed by Cytokine PharmaSciences and Baxalta, which was purchased by Shire Pharmaceuticals.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-265-1mg | 1mg | 3090 | ||
GMP-Bios-ab-265-10mg | 10mg | 21890 | ||
GMP-Bios-ab-265-100mg | 100mg | 148000 | ||
GMP-Bios-ab-265-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Imalumab biosimilar, Whole mAb, Anti-MIF Antibody: Anti-GIF/GLIF/MMIF therapeutic antibody |
INN Name | Imalumab |
Target | MIF |
Format | Whole mAb |
Derivation | Human |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Discontinued |
100% SI Structure | 6foe:HL:AB |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2014 |
Year Recommended | 2015 |
Companies | Cytokine PharmaSciences;Baxalta;Shire;Takeda |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Solid tumours;Lupus nephritis |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
